PBLA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBLA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-13), the Trailing Annual Dividend Yield of Panbela Therapeutics is 0.00%.
The historical rank and industry rank for Panbela Therapeutics's Dividend Yield % or its related term are showing as below:
Panbela Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.
As of today (2024-06-13), the Forward Dividend Yield % of Panbela Therapeutics is 0.00%.
Panbela Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Panbela Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panbela Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Panbela Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Dividend Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Panbela Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Panbela Therapeutics's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Panbela Therapeutics (OTCPK:PBLA) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Panbela Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer K. Simpson | director, officer: President and CEO | C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019 |
Susan Horvath | officer: V.P. of Finance & CFO | 4645 ITHACA LANE, PLYMOUTH MN 55446 |
Jeffrey E. Jacob | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Daniel Donovan | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Paul W. Schaffer | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Arthur Fratamico | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Ryan R. Gilbertson 2012 Irrevocable Trust | 10 percent owner | 1000 PARKER'S LAKE RD, WAYZATA MN 55391 |
Ryan Randall Gilbertson | 10 percent owner | 130 LAKE ST. WEST, WAYZATA MN 55391 |
Donald Robert Schemel | director | 712 VISTA BLVD #305, WACONIA MN 55387 |
Dalvir S Gill | director | 712 VISTA BLVD SUITE 305, WACONIA MN 55387 |
Scott Kellen | officer: Chief Financial Officer | 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447 |
Jeffrey S Mathiesen | director | 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167 |
Paulson J Robert Jr | director | |
Daniel E. Ryweck | officer: Chief Financial Officer | 712 VISTA BLVD #305, WACONIA MN 55387 |
Michael T. Cullen | director | 712 VISTA BLVD, #305, WACONIA MN 55387 |
From GuruFocus
By Marketwired • 07-10-2023
By Marketwired • 09-19-2023
By sperokesalga sperokesalga • 03-01-2023
By Marketwired • 07-17-2023
By Marketwired • 06-28-2023
By Marketwired • 09-26-2023
By Marketwired • 08-14-2023
By sperokesalga sperokesalga • 02-13-2023
By Marketwired • 07-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.